BioVersys, a Basel, Switzerland-based privately held scientific stage, multi-asset pharmaceutical firm, prolonged its Series C funding to CHF 32.6M.
The spherical was led by AMR Action Fund. Carly Levine, PhD, of the AMR Action Fund will be part of BioVersys’ board of administrators.
Led by Dr. Marc Gitzinger, BioVersys is a scientific stage pharmaceutical firm specializing in analysis and growth of small molecules appearing on novel bacterial targets with purposes in antimicrobial resistance (AMR) and focused microbiome modulation.
The firm intends to use the funds for the scientific growth of BV100, a possible hospital antibiotic concentrating on probably the most drug-resistant bacterial pathogen, Acinetobacter baumannii.